Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
A scientist in a lab looks into a microscope, which is placed on a desk. His face is not fully visible but he wears a lab coat and sits in front of a computer. Concept image for cell therapy, stem cell research, phase 1 clinical trial, and geographic atrophy associated with age-related macular degeneration. Image credit: ©CoetzeeRising/peopleimages.com – stock.adobe.com

Eyestem Research announces positive results from phase 1 geographic atrophy trial

Martin David Harp
April 14th 2025
Article

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

An image of a person pressing a computer shutdown button, superimposed digitally over the image. Concept for clinical trial discontinuation. Image credit: ©natali_mis – stock.adobe.com

Opthea discontinues COAST and ShORe sozinibercept combination therapy trials

Martin David Harp
April 2nd 2025
Article

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration

An elderly man and his caregiver discuss their budget and financial well-being. Concept image for caretaker, caregiver, aging, age-related macular degeneration. Image credit: ©Andrii Lysenko – stock.adobe.com

International study illuminates economic burden of late-stage age-related macular degeneration

Lynda Charters
March 31st 2025
Article

Researchers assessed the costs to patients and caregivers in Germany, Bulgaria and the US

Two boxes, labeled "yes" and "no." There is a red checkmark in the "no" box. Concept portraying an ophthalmic clinical trial which does not meet its endpoint. Image credit: ©Matthew Benoit – stock.adobe.com

Phase 3 COAST trial fails to meet primary endpoints for wet AMD, Opthea reports

Martin David Harp
March 24th 2025
Article

The Combination OPT-302 with Aflibercept Study (COAST) evaluated sozinibercept 2 mg in combination with aflibercept 2 mg for wet age-related macular degeneration

Rows of medical syringes in sanitary packaging. Concept image for aflibercept intravitreal eye injection. ©Titolino – stock.adobe.com

Study examines real-world treat-and-extend outcomes and background factors of macular atrophy

Lynda Charters
March 21st 2025
Article

The study demonstrated that the number of injections needed gradually decreased during the follow-up period

A blue hazard sign, an exclamation point (!) inside a triangle, to communicate the risks of misdiagnosing geographic atrophy and age-related macular degeneration. Image credit: ©jcsnb – stock.adobe.com

Researchers raise awareness of macular pathologies which mimic AMD and GA

Lynda Charters
March 20th 2025
Article

Inherited retinal diseases have disease processes distinct from age-related macular degeneration and geographic atrophy, but may present with "phenocopy" clinical signs

© 2025 MJH Life Sciences

All rights reserved.